3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts

FomoAnxiety · 2026-03-09T12:51:22+00:00

Top Wall Street analysts recommend three stocks as strong buys: Aktis Oncology, SOLV Energy, and Immuneering, all recently receiving positive ratings and significant upside potential according to analyst price targets.

FomoAnxiety

2026-03-09 12:51:22

Abstract generation in progress

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

Aktis Oncology AKTS -8.42% ▼ – Aktis Oncology is a clinical-stage biotech company developing targeted radiotherapy drugs designed to treat solid tumors. Today, H.C. Wainwright analyst Robert Burns initiated coverage on the stock with a Buy rating and a price target of $30. In the last three months, all four Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 66.56%.

SOLV Energy MWH -5.02% ▼ – SOLV Energy is a renewable energy company that builds and operates large-scale solar and energy storage projects. Today, Wolfe Research analyst Steve Fleishman maintained a Buy rating on the stock with a $35 price target. In the last three months, all nine Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 26.96%.

Immuneering IMRX +7.03% ▲ – Immuneering is a clinical-stage biotech company developing targeted therapies for cancer. Today, Needham analyst Ami Fadia maintained a Buy rating on the stock with an $11 price target. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 168.86%.

Who Are the Top Analysts?

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.